331 related articles for article (PubMed ID: 36439976)
41. Design, synthesis, modeling studies and biological screening of novel pyrazole derivatives as potential analgesic and anti-inflammatory agents.
Taher AT; Mostafa Sarg MT; El-Sayed Ali NR; Hilmy Elnagdi N
Bioorg Chem; 2019 Aug; 89():103023. PubMed ID: 31185391
[TBL] [Abstract][Full Text] [Related]
42. Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.
Shaikh J; Patel K; Khan T
Mini Rev Med Chem; 2022; 22(8):1197-1215. PubMed ID: 34711160
[TBL] [Abstract][Full Text] [Related]
43. Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation.
Verma R; Verma SK; Rakesh KP; Girish YR; Ashrafizadeh M; Sharath Kumar KS; Rangappa KS
Eur J Med Chem; 2021 Feb; 212():113134. PubMed ID: 33395624
[TBL] [Abstract][Full Text] [Related]
44. Antiviral Activities of Pyridine Fused and Pyridine Containing Heterocycles, A Review (from 2000 to 2020).
Alizadeh SR; Ebrahimzadeh MA
Mini Rev Med Chem; 2021; 21(17):2584-2611. PubMed ID: 33573543
[TBL] [Abstract][Full Text] [Related]
45. Current progress on antioxidants incorporating the pyrazole core.
Silva VLM; Elguero J; Silva AMS
Eur J Med Chem; 2018 Aug; 156():394-429. PubMed ID: 30015075
[TBL] [Abstract][Full Text] [Related]
46. Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview.
Lang DK; Kaur R; Arora R; Saini B; Arora S
Anticancer Agents Med Chem; 2020; 20(18):2150-2168. PubMed ID: 32628593
[TBL] [Abstract][Full Text] [Related]
47. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals.
Vitaku E; Smith DT; Njardarson JT
J Med Chem; 2014 Dec; 57(24):10257-74. PubMed ID: 25255204
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors.
Abdellatif KRA; Fadaly WAA; Kamel GM; Elshaier YAMM; El-Magd MA
Bioorg Chem; 2019 Feb; 82():86-99. PubMed ID: 30278282
[TBL] [Abstract][Full Text] [Related]
49. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
[TBL] [Abstract][Full Text] [Related]
50. Comparison of Conventional and Microwave Synthesis of Phenyl-1H-pyrazoles and Phenyl-1H-pyrazoles-4-carboxylic Acid Derivatives.
Machado AS; de Carvalho FS; Mouraa RBP; Chaves LS; Lião LM; Sanz G; Vaz BG; Rodrigues MF; Romão W; Menegatti R; Silva GNS
Curr Org Synth; 2021; 18(8):844-853. PubMed ID: 34886771
[TBL] [Abstract][Full Text] [Related]
51. In Vitro Evaluation and Bioinformatics Analysis of Schiff Bases Bearing Pyrazole Scaffold as Bioactive Agents: Antioxidant, Anti-Diabetic, Anti-Alzheimer, and Anti-Arthritic.
Alkahtani HM; Almehizia AA; Al-Omar MA; Obaidullah AJ; Zen AA; Hassan AS; Aboulthana WM
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894604
[TBL] [Abstract][Full Text] [Related]
52. Application and synthesis of thiazole ring in clinically approved drugs.
Niu ZX; Wang YT; Zhang SN; Li Y; Chen XB; Wang SQ; Liu HM
Eur J Med Chem; 2023 Mar; 250():115172. PubMed ID: 36758304
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and Functionalization of Coumarin-Pyrazole Scaffold: Recent Development, Challenges, and Opportunities.
Jadhav NK; Kale BR; Alam MS; Gaikwad VB; Prasad V; Kale RR
Curr Org Synth; 2021 Oct; 18(7):685-710. PubMed ID: 33645484
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic evolution of benzimidazole derivatives in the last quinquennial period.
Akhtar W; Khan MF; Verma G; Shaquiquzzaman M; Rizvi MA; Mehdi SH; Akhter M; Alam MM
Eur J Med Chem; 2017 Jan; 126():705-753. PubMed ID: 27951484
[TBL] [Abstract][Full Text] [Related]
55. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities.
Akhtar J; Khan AA; Ali Z; Haider R; Shahar Yar M
Eur J Med Chem; 2017 Jan; 125():143-189. PubMed ID: 27662031
[TBL] [Abstract][Full Text] [Related]
56. Synthesis of Chromone-Related Pyrazole Compounds.
Santos CMM; Silva VLM; Silva AMS
Molecules; 2017 Oct; 22(10):. PubMed ID: 28981465
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of anti-inflammatory, analgesic activities, and side effects of some pyrazole derivatives.
Domiati S; El-Mallah A; Ghoneim A; Bekhit A; El Razik HA
Inflammopharmacology; 2016 Aug; 24(4):163-72. PubMed ID: 27342269
[TBL] [Abstract][Full Text] [Related]
58. From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles.
Delost MD; Smith DT; Anderson BJ; Njardarson JT
J Med Chem; 2018 Dec; 61(24):10996-11020. PubMed ID: 30024747
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors.
Gedawy EM; Kassab AE; El Kerdawy AM
Eur J Med Chem; 2020 Mar; 189():112066. PubMed ID: 31982653
[TBL] [Abstract][Full Text] [Related]
60. Pyrazole containing natural products: synthetic preview and biological significance.
Kumar V; Kaur K; Gupta GK; Sharma AK
Eur J Med Chem; 2013 Nov; 69():735-53. PubMed ID: 24099993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
